190 related articles for article (PubMed ID: 11733495)
1. Interferon-gamma-mediated activation and ubiquitin-proteasome-dependent degradation of PPARgamma in adipocytes.
Floyd ZE; Stephens JM
J Biol Chem; 2002 Feb; 277(6):4062-8. PubMed ID: 11733495
[TBL] [Abstract][Full Text] [Related]
2. Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation.
Hauser S; Adelmant G; Sarraf P; Wright HM; Mueller E; Spiegelman BM
J Biol Chem; 2000 Jun; 275(24):18527-33. PubMed ID: 10748014
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor alpha (PPARalpha ) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genes.
Blanquart C; Barbier O; Fruchart JC; Staels B; Glineur C
J Biol Chem; 2002 Oct; 277(40):37254-9. PubMed ID: 12118000
[TBL] [Abstract][Full Text] [Related]
4. Urban renewal in the nucleus: is protein turnover by proteasomes absolutely required for nuclear receptor-regulated transcription?
Nawaz Z; O'Malley BW
Mol Endocrinol; 2004 Mar; 18(3):493-9. PubMed ID: 14673136
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome-proliferator-activated receptor gamma suppresses Wnt/beta-catenin signalling during adipogenesis.
Moldes M; Zuo Y; Morrison RF; Silva D; Park BH; Liu J; Farmer SR
Biochem J; 2003 Dec; 376(Pt 3):607-13. PubMed ID: 12954078
[TBL] [Abstract][Full Text] [Related]
6. A role for C/EBPbeta in regulating peroxisome proliferator-activated receptor gamma activity during adipogenesis in 3T3-L1 preadipocytes.
Hamm JK; Park BH; Farmer SR
J Biol Chem; 2001 May; 276(21):18464-71. PubMed ID: 11279134
[TBL] [Abstract][Full Text] [Related]
7. Interferon-gamma-induced regulation of peroxisome proliferator-activated receptor gamma and STATs in adipocytes.
Waite KJ; Floyd ZE; Arbour-Reily P; Stephens JM
J Biol Chem; 2001 Mar; 276(10):7062-8. PubMed ID: 11106650
[TBL] [Abstract][Full Text] [Related]
8. Involvement of suppressor for Gal 1 in the ubiquitin/proteasome-mediated degradation of estrogen receptors.
Masuyama H; Hiramatsu Y
J Biol Chem; 2004 Mar; 279(13):12020-6. PubMed ID: 14702340
[TBL] [Abstract][Full Text] [Related]
9. Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells.
Motomura W; Takahashi N; Nagamine M; Sawamukai M; Tanno S; Kohgo Y; Okumura T
Int J Cancer; 2004 Jan; 108(1):41-6. PubMed ID: 14618613
[TBL] [Abstract][Full Text] [Related]
10. Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin.
Werman A; Hollenberg A; Solanes G; Bjorbaek C; Vidal-Puig AJ; Flier JS
J Biol Chem; 1997 Aug; 272(32):20230-5. PubMed ID: 9242701
[TBL] [Abstract][Full Text] [Related]
11. A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors.
Perissi V; Aggarwal A; Glass CK; Rose DW; Rosenfeld MG
Cell; 2004 Feb; 116(4):511-26. PubMed ID: 14980219
[TBL] [Abstract][Full Text] [Related]
12. PPARgamma ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p21 pathway.
Han C; Demetris AJ; Michalopoulos GK; Zhan Q; Shelhamer JH; Wu T
Hepatology; 2003 Jul; 38(1):167-77. PubMed ID: 12829999
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect.
Armoni M; Kritz N; Harel C; Bar-Yoseph F; Chen H; Quon MJ; Karnieli E
J Biol Chem; 2003 Aug; 278(33):30614-23. PubMed ID: 12777391
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells.
Qin C; Burghardt R; Smith R; Wormke M; Stewart J; Safe S
Cancer Res; 2003 Mar; 63(5):958-64. PubMed ID: 12615709
[TBL] [Abstract][Full Text] [Related]
15. Importance of the regulation of nuclear receptor degradation.
Dennis AP; Haq RU; Nawaz Z
Front Biosci; 2001 Aug; 6():D954-9. PubMed ID: 11487464
[TBL] [Abstract][Full Text] [Related]
16. The identification and characterization of a STAT 1 binding site in the PPARgamma2 promoter.
Hogan JC; Stephens JM
Biochem Biophys Res Commun; 2001 Sep; 287(2):484-92. PubMed ID: 11554754
[TBL] [Abstract][Full Text] [Related]
17. NPDC-1, a novel regulator of neuronal proliferation, is degraded by the ubiquitin/proteasome system through a PEST degradation motif.
Spencer ML; Theodosiou M; Noonan DJ
J Biol Chem; 2004 Aug; 279(35):37069-78. PubMed ID: 15229225
[TBL] [Abstract][Full Text] [Related]
18. Specific ubiquitin-conjugating enzymes promote degradation of specific nuclear receptor coactivators.
Yan F; Gao X; Lonard DM; Nawaz Z
Mol Endocrinol; 2003 Jul; 17(7):1315-31. PubMed ID: 12663742
[TBL] [Abstract][Full Text] [Related]
19. Caspase-mediated degradation of PPARgamma proteins in adipocytes.
He F; Doucet JA; Stephens JM
Obesity (Silver Spring); 2008 Aug; 16(8):1735-41. PubMed ID: 18497737
[TBL] [Abstract][Full Text] [Related]
20. The E3 ubiquitin ligase TRIM25 regulates adipocyte differentiation via proteasome-mediated degradation of PPARĪ³.
Lee JM; Choi SS; Lee YH; Khim KW; Yoon S; Kim BG; Nam D; Suh PG; Myung K; Choi JH
Exp Mol Med; 2018 Oct; 50(10):1-11. PubMed ID: 30323259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
